Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Colon Cancer | Review

Role of long non-coding RNAs in metabolic reprogramming of gastrointestinal cancer cells

Authors: Kang Wang, Yan Lu, Haibin Li, Jun Zhang, Yongle Ju, Manzhao Ouyang

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Metabolic reprogramming, which is recognized as a hallmark of cancer, refers to the phenomenon by which cancer cells change their metabolism to support their increased biosynthetic demands. Tumor cells undergo substantial alterations in metabolic pathways, such as glycolysis, oxidative phosphorylation, pentose phosphate pathway, tricarboxylic acid cycle, fatty acid metabolism, and amino acid metabolism. Latest studies have revealed that long non-coding RNAs (lncRNAs), a group of non-coding RNAs over 200 nucleotides long, mediate metabolic reprogramming in tumor cells by regulating the transcription, translation and post-translational modification of metabolic-related signaling pathways and metabolism-related enzymes through transcriptional, translational, and post-translational modifications of genes. In addition, lncRNAs are closely related to the tumor microenvironment, and they directly or indirectly affect the proliferation and migration of tumor cells, drug resistance and other processes. Here, we review the mechanisms of lncRNA-mediated regulation of glucose, lipid, amino acid metabolism and tumor immunity in gastrointestinal tumors, aiming to provide more information on effective therapeutic targets and drug molecules for gastrointestinal tumors.

Graphical Abstract

Literature
1.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
3.
Perusina Lanfranca M, Thompson JK, Bednar F, et al. Metabolism and epigenetics of pancreatic cancer stem cells. Semin Cancer Biol. 2019;57:19–26.PubMedCrossRef
4.
5.
6.
Hu Q, Qin Y, Ji S, et al. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Lett. 2019;452:226–36.PubMedCrossRef
7.
Choi S, Yoo YJ, Kim H, et al. Clinical and biochemical relevance of monounsaturated fatty acid metabolism targeting strategy for cancer stem cell elimination in colon cancer. Biochem Biophys Res Commun. 2019;519(1):100–5.PubMedCrossRef
8.
Pes GM, Errigo A, Soro S, et al. Glucose-6-phosphate dehydrogenase deficiency reduces susceptibility to cancer of endodermal origin. Acta Oncol. 2019;58(9):1205–11.PubMedCrossRef
9.
Zou RC, Xiao SF, Shi ZT, et al. Identification of metabolism-associated pathways and genes involved in male and female liver cancer patients. J Theor Biol. 2019;480:218–28.PubMedCrossRef
10.
Kouba S, Ouldamer L, Garcia C, et al. Lipid metabolism and calcium signaling in epithelial ovarian cancer. Cell Calcium. 2019;81:38–50.PubMedCrossRef
11.
Tao L, Yu H, Liang R, et al. Rev-erbalpha inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells. Oncogenesis. 2019;8(10):57.PubMedPubMedCentralCrossRef
12.
13.
Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.PubMedPubMedCentralCrossRef
14.
Sunwoo H, Dinger ME, Wilusz JE, et al. MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome Res. 2009;19(3):347–59.PubMedPubMedCentralCrossRef
15.
Wilusz JE, Freier SM, Spector DL. 3’ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008;135(5):919–32.PubMedPubMedCentralCrossRef
16.
Katayama S, Tomaru Y, Kasukawa T, et al. Antisense transcription in the mammalian transcriptome. Science. 2005;309(5740):1564–6.PubMedCrossRef
17.
18.
19.
20.
Liu L, Liu Z, Liu Q, et al. LncRNA INHEG promotes glioma stem cell maintenance and tumorigenicity through regulating rRNA 2’-O-methylation. Nat Commun. 2023;14(1):7526.PubMedPubMedCentralCrossRef
21.
Liu X, Zhu Q, Guo Y, et al. LncRNA LINC00689 promotes the growth, metastasis and glycolysis of glioma cells by targeting miR-338-3p/PKM2 axis. Biomed Pharmacother. 2019;117:109069.PubMedCrossRef
22.
23.
Liao M, Liao W, Xu N, et al. LncRNA EPB41L4A-AS1 regulates glycolysis and glutaminolysis by mediating nucleolar translocation of HDAC2. EBioMedicine. 2019;41:200–13.PubMedPubMedCentralCrossRef
24.
Lis P, Dylag M, Niedzwiecka K, et al. The HK2 dependent “warburg effect” and mitochondrial oxidative phosphorylation in cancer: targets for effective therapy with 3-bromopyruvate. Molecules. 2016;21(12):1730.PubMedPubMedCentralCrossRef
25.
Zheng J, Luo J, Zeng H, et al. (125)I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma. Biomed Pharmacother. 2019;119:109402.PubMedCrossRef
26.
de Andrade Barreto E, de Souza Santos PT, Bergmann A, et al. Alterations in glucose metabolism proteins responsible for the Warburg effect in esophageal squamous cell carcinoma. Exp Mol Pathol. 2016;101(1):66–73.PubMedCrossRef
27.
Wang S, Zhang Y, Cai Q, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression. Mol Cancer. 2019;18(1):145.PubMedPubMedCentralCrossRef
28.
Dai W, Meng X, Mo S, et al. FOXE1 represses cell proliferation and Warburg effect by inhibiting HK2 in colorectal cancer. Cell Commun Signal. 2020;18(1):7.PubMedPubMedCentralCrossRef
29.
Yang L, Zhang W, Wang Y, et al. Hypoxia-induced miR-214 expression promotes tumour cell proliferation and migration by enhancing the Warburg effect in gastric carcinoma cells. Cancer Lett. 2018;414:44–56.PubMedCrossRef
30.
Wang XX, Yin GQ, Zhang ZH, et al. TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Exp Cell Res. 2020;386(1):111713.PubMedCrossRef
31.
Xu D, Jin J, Yu H, et al. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. J Exp Clin Cancer Res. 2017;36(1):44.PubMedPubMedCentralCrossRef
32.
Xu Q, Tu J, Dou C, et al. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma. Mol Cancer. 2017;16(1):178.PubMedPubMedCentralCrossRef
33.
Wang H, Peng R, Chen X, et al. Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer. Oncol Lett. 2018;15(4):5553–60.PubMedPubMedCentral
34.
Vaz CV, Marques R, Alves MG, et al. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J Cancer Res Clin Oncol. 2016;142(1):5–16.PubMedCrossRef
35.
Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95(7):912–9.PubMedCrossRef
36.
Karageorgis G, Reckzeh ES, Ceballos J, et al. Chromopynones are pseudo natural product glucose uptake inhibitors targeting glucose transporters GLUT-1 and -3. Nat Chem. 2018;10(11):1103–11.PubMedCrossRef
37.
Munemoto M, Mukaisho KI, Miyashita T, et al. Roles of the hexosamine biosynthetic pathway and pentose phosphate pathway in bile acid-induced cancer development. Cancer Sci. 2019;110(8):2408–20.PubMedPubMedCentralCrossRef
38.
39.
Feng J, Ma J, Liu S, et al. A noncoding RNA LINC00504 interacts with c-Myc to regulate tumor metabolism in colon cancer. J Cell Biochem. 2019;120(9):14725–34.PubMedCrossRef
40.
41.
42.
Huang JZ, Chen M, Chen D, et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell. 2017;68(1):171-184 e6.PubMedCrossRef
43.
Bian Z, Zhang J, Li M, et al. LncRNA-FEZF1-AS1 Promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res. 2018;24(19):4808–19.PubMedCrossRef
44.
Cui S, Yang X, Zhang L, et al. LncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. Biochem Biophys Res Commun. 2018;506(1):251–8.PubMedCrossRef
45.
Guo X, Zhang Y, Liu L, et al. HNF1A-AS1 regulates cell migration, invasion and glycolysis via modulating miR-124/MYO6 in colorectal cancer cells. Onco Targets Ther. 2020;13:1507–18.PubMedPubMedCentralCrossRef
46.
Ellis BC, Graham LD, Molloy PL. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta. 2014;1843(2):372–86.PubMedCrossRef
47.
Sun S, Li W, Ma X, et al. Long noncoding RNA LINC00265 promotes glycolysis and lactate production of colorectal cancer through regulating of miR-216b-5p/TRIM44 Axis. Digestion. 2020;101(4):391–400.PubMedCrossRef
48.
Wang J, Lei ZJ, Guo Y, et al. miRNA-regulated delivery of lincRNA-p21 suppresses beta-catenin signaling and tumorigenicity of colorectal cancer stem cells. Oncotarget. 2015;6(35):37852–70.PubMedPubMedCentralCrossRef
49.
Tang D, Yang Z, Long F, et al. Long noncoding RNA MALAT1 mediates stem cell-like properties in human colorectal cancer cells by regulating miR-20b-5p/Oct4 axis. J Cell Physiol. 2019;234(11):20816–28.PubMedCrossRef
50.
Bai J, Xu J, Zhao J, et al. Downregulation of lncRNA AWPPH inhibits colon cancer cell proliferation by downregulating GLUT-1. Oncol Lett. 2019;18(2):2007–12.PubMedPubMedCentral
51.
Cui Z, Wang Q, Deng MH, et al. LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis. Cancer Biomark. 2022;34(1):41–53.PubMedCrossRef
52.
Zhao Y, Liu Y, Lin L, et al. The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Mol Cancer. 2018;17(1):69.PubMedPubMedCentralCrossRef
53.
Zhu L, Jia R, Zhang J, et al. Quantitative proteomics analysis revealed the potential role of lncRNA Ftx in promoting gastric cancer progression. Proteomics Clin Appl. 2020;14(1):e1900053.PubMedCrossRef
54.
Qian Y, Song W, Wu X, et al. DLX6 Antisense RNA 1 modulates glucose metabolism and cell growth in gastric cancer by targeting microRNA-4290. Dig Dis Sci. 2021;66(2):460–73.PubMedCrossRef
55.
Yan B, Ren Z, Sun J, et al. IGF2-AS knockdown inhibits glycolysis and accelerates apoptosis of gastric cancer cells through targeting miR-195/CREB1 axis. Biomed Pharmacother. 2020;130:110600.PubMedCrossRef
56.
Jin X, Qiao L, Fan H, et al. Long non-coding RNA MSC-AS1 facilitates the proliferation and glycolysis of gastric cancer cells by regulating PFKFB3 expression. Int J Med Sci. 2021;18(2):546–54.PubMedPubMedCentralCrossRef
57.
Deng P, Li K, Gu F, et al. LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis. Mol Med. 2021;27(1):9.PubMedPubMedCentralCrossRef
58.
Xu J, Xu Y, Ye G, et al. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J Chemother. 2023;35(6):527–38.PubMedCrossRef
59.
60.
Li X, Zhao Q, Qi J, et al. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARgamma pathway in hepatocellular carcinoma. Int J Oncol. 2018;53(2):551–66.PubMedPubMedCentral
61.
Zheng Q, Lin Z, Xu J, et al. Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting beta-catenin by activating PKM2 and inactivating PTEN. Cell Death Dis. 2018;9(3):253.PubMedPubMedCentralCrossRef
62.
Wu M, An J, Zheng Q, et al. Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR. Oncotarget. 2016;7(41):66525–39.PubMedPubMedCentralCrossRef
63.
Zheng YL, Li L, Jia YX, et al. LINC01554-Mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway. Theranostics. 2019;9(3):796–810.PubMedPubMedCentralCrossRef
64.
65.
Guan YF, Huang QL, Ai YL, et al. Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis. Oncogene. 2020;39(11):2408–23.PubMedPubMedCentralCrossRef
66.
Zhou Y, Huang Y, Hu K, et al. HIF1A activates the transcription of lncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p. Cell Death Dis. 2020;11(3):176.PubMedPubMedCentralCrossRef
67.
Luo F, Liu X, Ling M, et al. The lncRNA MALAT1, acting through HIF-1alpha stabilization, enhances arsenite-induced glycolysis in human hepatic L-02 cells. Biochim Biophys Acta. 2016;1862(9):1685–95.PubMedCrossRef
68.
Liang Y, Zhang D, Zheng T, et al. lncRNA-SOX2OT promotes hepatocellular carcinoma invasion and metastasis through miR-122-5p-mediated activation of PKM2. Oncogenesis. 2020;9(5):54.PubMedPubMedCentralCrossRef
69.
Shang R, Wang M, Dai B, et al. Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway. Mol Oncol. 2020;14(6):1381–96.PubMedPubMedCentralCrossRef
70.
Yu W, Dai Y. lncRNA LOXL1-AS1 promotes liver cancer cell proliferation and migration by regulating the miR-377-3p/NFIB axis. Oncol Lett. 2021;22(2):624.PubMedPubMedCentralCrossRef
71.
Wang F, Hu Y, Wang H, et al. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2. J Exp Clin Cancer Res. 2023;42(1):267.PubMedPubMedCentralCrossRef
72.
Zhao B, Cao P, Hu S, et al. LncRNA-NBAT-1 modulates esophageal cancer proliferation via PKM2. Am J Transl Res. 2019;11(9):5978–87.PubMedPubMedCentral
73.
Ma J, Fan Y, Feng T, et al. HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression. Oncotarget. 2017;8(49):86410–22.PubMedPubMedCentralCrossRef
74.
75.
Li W, Huang K, Wen F, et al. LINC00184 silencing inhibits glycolysis and restores mitochondrial oxidative phosphorylation in esophageal cancer through demethylation of PTEN. EBioMedicine. 2019;44:298–310.PubMedPubMedCentralCrossRef
76.
Liu H, Zhang Q, Song Y, et al. Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression. J Exp Clin Cancer Res. 2021;40(1):287.PubMedPubMedCentralCrossRef
77.
Huang X, Liu C, Li H, et al. Hypoxia-responsive lncRNA G077640 promotes ESCC tumorigenesis via the H2AX-HIF1α-glycolysis axis. Carcinogenesis. 2023;44(5):383–93.PubMedCrossRef
78.
Qi C, Xiaofeng C, Dongen L, et al. Long non-coding RNA MACC1-AS1 promoted pancreatic carcinoma progression through activation of PAX8/NOTCH1 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):344.PubMedPubMedCentralCrossRef
79.
Ma Y, Hu M, Zhou L, et al. Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2. Oncol Lett. 2019;18(3):2212–9.PubMedPubMedCentral
80.
Xu Z, Zhang D, Zhang Z, et al. MicroRNA-505, suppressed by oncogenic long non-coding RNA LINC01448, acts as a novel suppressor of glycolysis and tumor progression through inhibiting HK2 expression in pancreatic cancer. Front Cell Dev Biol. 2020;8:625056.PubMedCrossRef
81.
Sun J, Zhang P, Yin T, et al. Upregulation of LncRNA PVT1 facilitates pancreatic ductal adenocarcinoma cell progression and glycolysis by regulating MiR-519d-3p and HIF-1A. J Cancer. 2020;11(9):2572–9.PubMedPubMedCentralCrossRef
82.
Hu Y, Tang J, Xu F, et al. A reciprocal feedback between N6-methyladenosine reader YTHDF3 and lncRNA DICER1-AS1 promotes glycolysis of pancreatic cancer through inhibiting maturation of miR-5586–5p. J Exp Clin Cancer Res. 2022;41(1):1–20.CrossRef
83.
Chen J, Yu Y, Li H, et al. Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Mol Cancer. 2019;18(1):33.PubMedPubMedCentralCrossRef
84.
Cheng C, Geng F, Cheng X, et al. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27.PubMed
85.
Lally JSV, Ghoshal S, DePeralta DK, et al. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29(1):174-182 e5.PubMedCrossRef
86.
Chuang HY, Lee YP, Lin WC, et al. Fatty acid inhibition sensitizes androgen-dependent and -independent prostate cancer to radiotherapy via FASN/NF-kappaB pathway. Sci Rep. 2019;9(1):13284.PubMedPubMedCentralCrossRef
87.
Aljohani A, Khan MI, Bonneville A, et al. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1alpha-FGF21 axis in mice. J Biol Chem. 2019;294(51):19475–85.PubMedPubMedCentralCrossRef
88.
Liao C, Li M, Li X, et al. Trichothecin inhibits invasion and metastasis of colon carcinoma associating with SCD-1-mediated metabolite alteration. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(2):158540.PubMedCrossRef
89.
Cruz-Gil S, Sanchez-Martinez R, Gomez de Cedron M, et al. Targeting the lipid metabolic axis ACSL/SCD in colorectal cancer progression by therapeutic miRNAs miR-19b-1 role. J Lipid Res. 2018;59(1):14–24.PubMedCrossRef
90.
Liu M, Yu X, Lin L, et al. ATGL promotes the proliferation of hepatocellular carcinoma cells via the p-AKT signaling pathway. J Biochem Mol Toxicol. 2019;33(11):e22391.PubMedCrossRef
91.
Christensen LL, True K, Hamilton MP, et al. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016;10(8):1266–82.PubMedPubMedCentralCrossRef
92.
Cui M, Xiao Z, Wang Y, et al. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res. 2015;75(5):846–57.PubMedCrossRef
93.
Liu X, Liang Y, Song R, et al. Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation. Mol Cancer. 2018;17(1):90.PubMedPubMedCentralCrossRef
94.
Xu K, Xia P, Gongye X, et al. A novel lncRNA RP11–386G1110 reprograms lipid metabolism to promote hepatocellular carcinoma progression. Mol Metab. 2022;63:101540.PubMedPubMedCentralCrossRef
95.
Ma J, Feng J, Zhou X. Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway. Exp Mol Pathol. 2020;115:104466.PubMedCrossRef
96.
Wang X, Li H, Lu X, et al. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Cell Death Dis. 2018;9(10):940.PubMedPubMedCentralCrossRef
97.
He W, Liang B, Wang C, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019;38(23):4637–54.PubMedPubMedCentralCrossRef
98.
Zhu K-G, Yang J, Zhu Y, et al. The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism. Cell Death Dis. 2023;14(10):708.PubMedPubMedCentralCrossRef
99.
Yang C, Ko B, Hensley CT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014;56(3):414–24.PubMedPubMedCentralCrossRef
100.
Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–84.PubMedPubMedCentralCrossRef
101.
Masisi BK, El Ansari R, Alfarsi L, et al. The role of glutaminase in cancer. Histopathology. 2020;76(4):498–508.PubMedCrossRef
102.
103.
Ducker GS, Ghergurovich JM, Mainolfi N, et al. Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017;114(43):11404–9.PubMedPubMedCentralCrossRef
104.
105.
Deng SJ, Chen HY, Zeng Z, et al. Nutrient stress-dysregulated antisense lncRNA GLS-AS impairs GLS-mediated metabolism and represses pancreatic cancer progression. Cancer Res. 2019;79(7):1398–412.PubMedCrossRef
106.
He J, Li F, Zhou Y, et al. LncRNA XLOC_006390 promotes pancreatic carcinogenesis and glutamate metabolism by stabilizing c-Myc. Cancer Lett. 2020;469:419–28.PubMedCrossRef
107.
Zeng B, Ye H, Chen J, et al. LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis. Oncotarget. 2017;8(69):113650–61.PubMedPubMedCentralCrossRef
108.
Lin C, Zhang Y, Chen Y, et al. Long noncoding RNA LINC01234 promotes serine hydroxymethyltransferase 2 expression and proliferation by competitively binding miR-642a-5p in colon cancer. Cell Death Dis. 2019;10(2):137.PubMedPubMedCentralCrossRef
109.
Jiang R, Tang J, Chen Y, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8:15129.PubMedPubMedCentralCrossRef
110.
Sang LJ, Ju HQ, Liu GP, et al. LncRNA CamK-A regulates Ca(2+)-signaling-mediated tumor microenvironment remodeling. Mol Cell. 2018;72(1):71-83.e7.PubMedCrossRef
111.
Zhang C, Wei S, Dai S, et al. The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development. J Immunother Cancer. 2023;11(5):e006230.PubMedPubMedCentralCrossRef
112.
Liu Y, Shi M, He X, et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022;15(1):52.PubMedPubMedCentralCrossRef
113.
114.
Zheng Z, Wu M, Li H, et al. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis. BMC Med. 2023;21(1):132.PubMedPubMedCentralCrossRef
115.
Zhang X, Ma D, Xuan B, et al. LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51. Oncogene. 2023;42(17):1374–91.PubMedCrossRef
116.
117.
118.
Xu J, Meng Q, Li X, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p. Cancer Res. 2019;79(19):4882–95.PubMedCrossRef
119.
Liu J, Chang J, Jiang Y, et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv Mater. 2019;31(33):e1902575.PubMedPubMedCentralCrossRef
120.
Eisenberg L, Eisenberg-Bord M, Eisenberg-Lerner A, et al. Metabolic alterations in the tumor microenvironment and their role in oncogenesis. Cancer Lett. 2020;484:65–71.PubMedCrossRef
121.
Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435–49.PubMedCrossRef
122.
Metadata
Title
Role of long non-coding RNAs in metabolic reprogramming of gastrointestinal cancer cells
Authors
Kang Wang
Yan Lu
Haibin Li
Jun Zhang
Yongle Ju
Manzhao Ouyang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03194-0

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

Establishment of disulfidptosis-related LncRNA signature as biomarkers in colon adenocarcinoma

Research

Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer

Research

LncRNA RASAL2-AS1 promotes METTL14-mediated m6A methylation in the proliferation and progression of head and neck squamous cell carcinoma

Review

Clinical applications and perspectives of circulating tumor DNA in gastric cancer

Research

USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer

Correction

Correction to: N6‑methyladenosine levels in peripheral blood RNA: a potential diagnostic biomarker for colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits